Strange DNA structures may drive cancer development
LJI researchers shed light on the role of TET enzymes in genomic stability and cancers
LJI researchers shed light on the role of TET enzymes in genomic stability and cancers
The international recognition reflects how LJI research is valued by scientific peers
Now we can see what they see — and help
New LJI research could keep cancer-fighting T cells from burning out before the job is done
LJI scientists develop new tool for understanding enzymatic activity linked to blood cancers and heart disease
Treating patients with anti-CTLA4 therapies prior to anti-PD1 treatment may be a promising strategy
National Cancer Institute support brings cancer researchers together to share key findings
Dr. Altman’s research into T cell activation opened the door to new therapies for inflammation, autoimmune diseases, cancers, and more.
In 2013, Dr. Vijayanand teamed up with Professor Christian Ottensmeier at the Cancer Center, University of Southampton, UK, to
Samuel Myers, Ph.D., studies the signaling circuits that drive the behavior of individual immune cells and ultimately orchestrate systemic immune responses.
New LJI research could guide the development of more effective cancer immunotherapies
Myers Lab to expand autoimmune disease research, cancer and more